Humulin I (Isofano)

Humulin I (Isofano) is a pharmaceutical product containing the active ingredient insulin human, supplied as a sterile injectable solution for intramuscular or subcutaneous administration. It is a biosynthetic form of human insulin, marketed in the European Union and available by prescription for the management of blood glucose levels in diabetes. The preparation is intended for use under the guidance of a healthcare professional and conforms to EU pharmaceutical standards.

Humulin I (Isofano) is used as a short‑acting insulin to help control hyperglycemia in patients with diabetes mellitus.

- To lower elevated blood glucose in type 1 diabetes when administered at mealtimes. - To provide supplemental insulin coverage for type 2 diabetes patients who require additional glycemic control. - To be used in insulin‑pump therapy or as a correction dose in conjunction with basal insulin regimens. - To assist in managing glucose levels during periods of stress, illness, or surgery when insulin requirements may increase.

Like other insulin preparations, Humulin I (Isofano) may be associated with adverse reactions that vary in frequency and severity.

Common: - Injection site pain, redness or swelling. - Mild hypoglycemia presenting as shakiness, sweating, or hunger. - Weight gain associated with improved glycemic control. - Lipodystrophy or skin thickening at repeated injection sites.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Persistent hypokalemia or electrolyte disturbances.

Healthcare providers should consider several precautionary measures when prescribing Humulin I (Isofano) to ensure safe and effective use.

- Verify patient’s diagnosis and insulin requirements before initiating therapy. - Monitor blood glucose regularly to adjust dose and avoid hypoglycemia. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Assess for a history of allergic reactions to insulin or excipients. - Educate patients on proper injection technique and rotation of sites. - Consider pregnancy status; insulin requirements may change during gestation. - Review concomitant medications that can mask hypoglycemia symptoms.

Humulin I (Isofano) can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment. - Beta‑blockers that may blunt hypoglycemia warning signs. - MAO‑inhibitors or certain antidepressants that can potentiate insulin’s glucose‑lowering effect.

Use with caution: - Oral hypoglycemic agents (e.g., sulfonylureas, meglitinides) may increase risk of hypoglycemia. - Corticosteroids, thiazide diuretics, or growth hormone can raise blood glucose, requiring dose changes. - Alcohol consumption can cause delayed hypoglycemia, especially when combined with insulin.